Isradipine Extended-Release Tabs Rx
Generic Name and Formulations:
Isradipine 5mg, 10mg; ext-rel tabs.
Indications for Isradipine Extended-Release Tabs:
Do not crush or chew. Initially 5mg once daily, alone or with a thiazide diuretic. May increase by 5mg/day at 2–4 week intervals; max 20mg/day.
CHF. GI narrowing (CR). Pregnancy (Cat.C). Nursing mothers: not recommended.
β-blockers may potentiate heart failure. Severe hypotension possible with fentanyl.
Calcium channel blocker (CCB) (dihydropyridine).
Dizziness, edema, palpitations, fatigue, flushing, dyspnea, GI upset, tachycardia, rash, pollakiuria, weakness, headache.
Formerly known under the brand name Dynacirc CR.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies